Dexcom has won a nod from FDA for the G7 15-Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes. With this clearance, the San Diego, CA-based company continues to ...
Introducing continuous glucose monitoring in primary care optimizes diabetes management in underserved populations.
Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI ...
New research from Montefiore Einstein investigators reveals that an underutilized tool, more commonly employed by ...
Among insulin-treated, CGM-naive adults, CGM initiation in primary care produced larger HbA1c reductions at 12 months and ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM ...
This diabetes technology offers a continuous stream of data to show a more complete picture of your blood sugars over time. This is different from a fingerstick meter that only represents that moment.
With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM’s for minimal life disruption “The approval of Eversense 365 represents a significant ...
MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, and Senseonics Holdings, Inc. (NYSE ...
Leveraging rapid technological advances for human health is a global trend, driving the rise of biomedical engineering research. An interdisciplinary research team, including the Faculty of ...
With the rising prevalence of diabetes worldwide, the demand for more efficient and real-time glucose monitoring solutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results